Hepatitis B Citations List: June 2025

Literature Citations

1. Development of Sulfamoylbenzamide-based Capsid Assembly Modulators for Hepatitis B Virus Capsid Assembly. Abbas, S.A., H.M. Cha, S. Nayak, S. Ahn, J. Gowda, I. Lieknina, A. Dislers, I.S. Kim, I. Jo, M. Kim, H. Kim, C. Ko, and S.B. Han. European Journal of Medicinal Chemistry, 2025. 290: 117430. PMID[40184774].
[PubMed]. HBV_06_2025.

2. Synthetic Interferon Exhibits Potent Antiviral Activity against HBV with the Potential for an Improved Safety Profile. Blair, W., Y.M. Loo, M. Bolton, L. Chen, Q.X. Liu, N. Sallada, R.P. Wang, E. Cho, A. Romero, T.H. Chang, A. Mercer, and C. Kurokawa. Journal of Hepatology, 2025. 82: S773. ISI[001504518600041].
[WOS]. HBV_06_2025.

3. RXR Agonist S169 Inhibits HBV/HDV Entry In Vitro by Disrupting KIF4-Dependent NTCP Trafficking. Gad, S.A., D.A. Abo Elwafa, S.A. Hussein, K. Fukano, T. Kato, I. Shoji, K. Chayama, M. Muramatsu, M. Isogawa, T. Wakita, D. Merk, and H.H. Aly. Antiviral Research, 2025. 240: 106214. PMID[40523562].
[PubMed]. HBV_06_2025.

4. Identification of Novel Therapeutic Targets in Hepatitis-B Virus-associated Membranous Nephropathy Using scRNA-seq and Machine Learning. Hu, Y., Q. An, X. Yu, and W. Jiang. Scientific Reports, 2025. 15(1): 18959. PMID[40442195]. PMCID[PMC12123029].
[PubMed]. HBV_06_2025.

5. In Vitro Characterization of Elebsiran (VIR-2218), an Investigational siRNA Therapeutic Targeting Hepatitis B Virus. Imam, H., J.Y. Zhou, J. Barry, T. Nguyen, A. Castoreno, F. Lempp, A. Cathcart, and G. Camus. Journal of Hepatology, 2025. 82. ISI[001504518600013].
[WOS]. HBV_06_2025.

6. Molecular Mechanisms of Hepatitis B Virus Entry Inhibition by a Bile Acid Derivative INT-767 Binding to the preS1 Region. Okumura, A., Y. Muraki, J. Arai, S. Nishimura, N. Inden, K. Sakamoto, T. Kitada, S. Kimoto, R. Kitano, T. Inoue, Y. Yamashita, Y. Iguchi, H. Ohashi, K. Watashi, T. Wakita, M. Une, and K. Ito. Antiviral Research, 2025. 240: 106213. PMID[40513783].
[PubMed]. HBV_06_2025.

7. Synthesis, Cytotoxicity, and Mechanistic Evaluation of 7-deazapurine-based Neplanocin Analogues as Selective Anti-HBV Agents. Samunuri, R., M. Toyama, M. Kasula, A.K. Jha, M. Okamoto, M. Baba, and A. Sharon. ChemistrySelect, 2025. 10(22): e00784. ISI[001504204600001].
[WOS]. HBV_06_2025.

8. Residual Viral Expression in siRNA-treated HBV-Replicating Cell and Mouse Models. Xu, M., Y. Qian, Z. Song, H. Wang, L. Yue, J. Liu, Y. Li, W. Zai, Z. Yuan, and J. Chen. Antiviral Research, 2025. 240: 106210. PMID[40482891].
[PubMed]. HBV_06_2025.

9. Therapy with Murinized Tobevibart and Elebsiran is Efficacious in a Liver-chimeric Mouse Model of HDV Infection. Zhou, J., H. Kaiser, E. Rocha, A.N. Terrell, D. Corti, L.A. Purcell, F.A. Lempp, and A.S. Puschnik. JHEP Reports, 2025. 7(6): 101400. PMID[40486136]. PMCID[PMC12143811].
[PubMed]. HBV_06_2025.

Patent Citations

This month, no relevant Hepatitis B patents were identified.